| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
AstraZeneca (NASDAQ:AZN) opened its expanded manufacturing facility in Coppell, Texas, following a $445 million investment to double production of Lokelma, a medication used to treat hyperkalemia.
The expansion adds a 9,000 square foot building with two manufacturing lines, enhanced laboratory testing capabilities, warehousing space, and additional administrative areas. The facility serves as the sole global manufacturing site for Lokelma, supplying more than 50 countries worldwide.
The Coppell facility employs more than 250 people and has operated for 10 years. The expansion forms part of AstraZeneca's announced $50 billion investment in US research and development and manufacturing over five years, which was disclosed in July 2025.
Posted In: AZN
